Dacarbazine是一种抗肿瘤剂，对黑色素瘤具有显着的活性。

Dacarbazine is an antineoplastic agent. It has significant activity against melanomas.

Treatment of Dacarbazine sensitizes melanomas to lysis of peptide-specific CTL and it is is mediated through Fas-independent pathway[2].

Treatment of combination of Axitinib and DTIC demonstrates significant antitumor activity against melanoma flank xenografts, reduces tumor cell proliferation and decreases the area of tumor necrosis and increases apoptosis. It also reduces meta-tasis-related factors and prolongs lifespan in mice[3].

Apotosis assay: UACC903 (UACC) cells treated with or without DTIC (20 μM) for 48 h are incubated with agonist anti-Fas Ab, CH-11 (500 ng/ml), for 5 and 16 h, respectively. To distinguish whether death/apoptosis is mediated by FasR, blocking anti-Fas Ab ZB4 (2 mg/ml) is added in the corresponding groups. At the end of incubation, cells are harvested and stained with propidium iodide and FITC-annexin V (BD PharMingen) for detecting apoptosis according to the instruction provided by the company. Ten thousand cells from each group are collected, and dead and apoptotic cells are analyzed without gating using CellQuest software. (Only for Reference)

4342-03-4

C6H10N6O

182.187

Imidazole Carboxamide;达卡巴嗪;DTIC-Dome

Ethanol:<1 mgml
DMSO:3 mg/mL (16.46 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years